Loading
Stereotactic body radiotherapy converges multiple beams with sub-millimetre accuracy to deliver tumour-destroying doses in one to five outpatient sessions, doing the job of surgery for inoperable early lung cancer and for metastases in liver, spine and brain. Tumour size and location limit its use, and late toxicity is a concern near the central airways.
Answer a few questions from a report and read the guideline statement that applies, quoted word for word with its source. Educational aids to prepare for an appointment, not advice.
Stereotactic body radiotherapy delivers ablative doses in 1-5 sessions by converging multiple non-coplanar beams with sub-millimetre accuracy, producing steep dose gradients that spare surrounding tissue. It is standard for inoperable early lung cancer, oligometastatic disease, liver, spine, and brain metastases (radiosurgery). SABR-COMET showed an overall survival benefit in oligometastatic disease, which underpins the idea of metastasis-directed therapy. Treatment is outpatient with minimal recovery, and SBRT pairs with immunotherapy in the hope of abscopal effects, though that benefit remains unproven in randomised trials. Limits are tumour size and location, with late toxicity a concern near central airways. The simple version is a few very high, very precise doses that can ablate a tumour much as surgery would.
Multiple non-coplanar beams converge with sub-millimetre accuracy; steep dose gradients.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"stereotactic body radiotherapy" OR ABSTRACT:"stereotactic body radiotherapy" OR TITLE:"stereotactic ablative radiotherapy" OR ABSTRACT:"stereotactic ablative radiotherapy" OR TITLE:"SBRT" OR ABSTRACT:"SBRT" OR TITLE:"SABR" OR ABSTRACT:"SABR"). Results are unfiltered search hits about SBRT / SABR (stereotactic radiotherapy), not a curated reading list.
Shares Amar U. Kishan, CROSSFIRE, A regulatory pathway for new radiotherapy techniques modelled on drug development, ViewRay (MRIdian) and the tag precision.
Shares Brainlab, Prizes for unpatentable surgical and radiotherapy techniques proven in trials, Partial nephrectomy, ablation & active surveillance of small renal masses, Rajiv Gandhi Cancer Institute and Research Centre and the tag precision.
Shares Joe Y. Chang, Theodore S. Hong, Hokkaido University Hospital, Apollo Hospitals (Apollo Cancer Centres) and the tag precision.
Shares Stereotactic ablative radiotherapy for oligometastatic disease, PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer, ORIOLE, Comprehensive Cancer Center Freiburg (CCCF) and the tag precision.
Shares Maximilian Diehn, HealthCare Global Enterprises, Champalimaud Foundation, Champalimaud Clinical Centre, A test to tell true oligometastatic disease from hidden widespread spread and the tag precision.
Shares A test to tell true oligometastatic disease from hidden widespread spread, The metastatic cascade, Recurrent and metastatic nasopharyngeal carcinoma, Precision roadmap: margins measured in millimetres → tests that find a target → doses fitted to the person → precision that changes outcomes and the tag precision.
Shares Maximilian Diehn, A test to tell true oligometastatic disease from hidden widespread spread, When the blood test is positive, hunt for the lesion with sensitive imaging, Hallmark: activating invasion and metastasis and the tag precision.
Shares B. S. Ajaikumar, Biopsy the one lesion that is growing while the others shrink, HealthCare Global Enterprises, Rajiv Gandhi Cancer Institute and Research Centre and the tag precision.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/